Expert Interview
Evaluation of AMGEN'S REPATHA® PHASE 3 VESALIUS-CV TRIAL
Ticker(s): AMGNA physician who manages patients with cardiovascular disease
How many patients do you manage with cardiovascular disease?
Added By: allan_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for AMGEN'S REPATHA® as a potential treatment for cardiovascular disease?
Added By: allan_adminDid this study support the recent label expansion for reduced CV risk?
Added By: pharmaadvisorAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
